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Vascular Outcomes in Patients With 
Screen-Detected or Clinically Diagnosed 
Type 2 Diabetes: Diabscreen Study 
Follow-up 
ABSTRACT
PURPOSE Screening guidelines for type 2 diabetes recommend targeting high-
risk individuals. Our objective was to assess whether diagnosis of type 2 diabetes 
based on opportunistic targeted screening results in lower vascular event rates 
compared with diagnosis on the basis of clinical signs or symptoms.
METHODS In a prospective, nonrandomized, observational study, we enrolled 
patients aged 45 to 75 years from 10 family practices in the Netherlands with a 
new diagnosis of type 2 diabetes, detected either by (1) opportunistic targeted 
screening (n = 359) or (2) clinical signs or symptoms (n = 206). Patients in both 
groups received the same guideline-concordant diabetes care. The main group 
outcome measure was a composite of death from cardiovascular disease (CVD), 
nonfatal myocardial infarction, and nonfatal stroke.
RESULTS Baseline vascular disease was more prevalent in the opportunistic tar-
geted screening group, mainly ischemic heart disease (12.3% vs 3.9%, P = .001) 
and nephropathy (16.9% vs 7.1%, P = .002). After a mean follow-up of 7.7 years 
(SD = 2.4 years) and 7.1 years (SD = 2.7 years) for the opportunistic targeted 
screening and clinical diagnosis groups, respectively, composite primary event 
rates did not differ signifi cantly between the 2 groups (9.5% vs 10.2%, P = .78; 
adjusted hazard ratio 0.67, 95% confi dence interval, 0.36-1.25; P = .21). There 
were also no signifi cant differences in the separate event rates of deaths from 
CVD, nonfatal myocardial infarction, and nonfatal strokes.
CONCLUSIONS Opportunistic targeted screening for type 2 diabetes detected 
patients with higher CVD morbidity at baseline when compared with clinical 
diagnosis but showed similar CVD mortality and major CVD morbidity after 7.7 
years. Opportunistic targeted screening and guided care appears to improve vas-
cular outcomes in type 2 diabetes in primary care.
Ann Fam Med 2013;11:20-27. doi:10.1370/afm.1460. 
INTRODUCTION
Targeting screening for type 2 diabetes to high-risk individuals is recommended for the prevention of vascular complications.1 The justiﬁ cation for the promotion of screening is that patients with 
type 2 diabetes are already at risk for developing microvascular complica-
tions before clinical diagnosis2 and have a twofold higher risk of cardiovas-
cular disease and mortality.3 The worldwide prevalence of type 2 diabetes 
is expected to keep rising in the next decade, dramatically increasing the 
burden of disease and health care costs.4,5
Glycemic control and cardiovascular risk management (mainly treat-
ment of hypertension and hypercholesterolemia) decrease vascular disease 
and mortality in patients with type 2 diabetes.6,7 It is currently uncertain, 
Erwin P. Klein Woolthuis, MD1
Wim J. C. de Grauw, MD, PhD1
Susanne M. van Keeken, MD1
Reinier P. Akkermans, MSc1
Eloy H. van de Lisdonk, MD, PhD1
Job F. M. Metsemakers, MD, PhD2
Chris van Weel, MD, PhD, FRCGP, 
FRACGP1
1Department of Primary and Community 
Care, Centre for Family Medicine, Geriatric 
Care and Public Health, Radboud Univer-
sity Nijmegen Medical Centre, Nijmegen, 
The Netherlands
2Department of Family Medicine, School 
for Public Health and Primary Care 
(CAPHRI), Maastricht University, Maas-
tricht, The Netherlands
Conﬂ icts of interest: authors report none.
CORRESPONDING AUTHOR
Erwin P. Klein Woolthuis, MD
Radboud University Nijmegen Medical 
Centre 
Department of Primary and Community 
Care, 117 ELG
PO Box 9101 
6500 HB Nijmegen, The Netherlands 
e.kleinwoolthuis@elg.umcn.nl
ANNALS OF FAMILY MEDICINE ✦ WWW.ANNFAMMED.ORG ✦ VOL. 11, NO. 1 ✦ JANUARY/FEBRUARY 2013
21
VASCUL AR OUTCOMES IN T YPE 2 DIABETES
however, whether treatment of patients with type 2 
diabetes detected through screening results in lower 
vascular event rates when compared with treatment of 
patients diagnosed by clinical signs or symptoms.6
To address this issue, we undertook a study that 
builds on a type 2 diabetes-screening program per-
formed by the Diabscreen study, in which diabetes 
screening was conducted during regular primary care 
in the Netherlands. The Diabscreen study reported a 
fair yield of opportunistic screening, targeting patients 
at high risk for undiagnosed type 2 diabetes who 
visited their family physician.8 After evaluation, the 
program was implemented in daily practice. Because 
of the continuous nature of the primary care setting of 
the program, we are now able to report a follow-up of 
up to 10 years after screening.
We compared outcomes in patients with type 2 
diabetes that had been diagnosed by opportunis-
tic targeted screening with outcomes of patients 
given a diagnosis after displaying diabetes signs or 
symptoms during the same period and in the same 
family practices. All patients had received the same 
guideline-concordant diabetes care after diagnosis, 
ie, the same glycemic control and cardiovascular risk 
management.9
Our main aim was to assess whether opportunistic 
targeted screening, compared with clinical diagnosis, 
would beneﬁ cially affect the risk of death from cardio-
vascular disease, myocardial infarction, and stroke.
METHODS
Participants and Setting
For the current Diabscreen study follow-up, data were 
available from 10 family practices in the Netherlands, 
all taking part in the Nijmegen Monitoring Project 
(NMP).10,11 The NMP is a practice-based research net-
work of the Radboud University Nijmegen Medical 
Centre, with an audit-enhanced monitoring system for 
chronic diseases such as type 2 diabetes. Despite this 
academic alliance, all participants are standard commu-
nity family practices.
Every individual in the Netherlands is registered 
with a family physician, and this registration is usu-
ally maintained over many years. Type 2 diabetes is 
commonly treated in primary care, and patients may 
consult a specialist only upon referral by the family 
physician.
We included data from all patients, aged 45 to 
75 years, with newly diagnosed type 2 diabetes who 
were enrolled in the monitoring system by their family 
physician between 1998 and 2005. For the purposes 
of this study, patients were not randomized into a 
subgroup but were selected by the detection method 
of their diabetes, as recorded in the NMP database: 
(1) type 2 diabetes detected by opportunistic targeted 
screening; or (2) clinically diagnosed type 2 diabe-
tes based on signs or symptoms. These 2 groups are 
described in detail.
Type 2 Diabetes by Opportunistic Targeted 
Screening
The opportunistic targeted screening procedure was 
based on the Diabscreen study, and some of the cur-
rent data were derived from that study.8 In brief, we 
considered patients to be at high risk for undiagnosed 
type 2 diabetes if they had 1 or more of the follow-
ing diabetes risk factors, derived from the American 
Diabetes Association (ADA) recommendations for 
screening for type 2 diabetes1: a family history of dia-
betes (deﬁ ned as diabetes in a parent, brother, sister, 
or a combination thereof); a history of cardiovascular 
disease (heart failure, ischemic heart disease, myo-
cardial infarction, transient cerebral ischemia, stroke, 
or peripheral arterial disease); obesity (body mass 
index [BMI] >27 kg/m2); hypertension (blood pressure 
≥140/90 mm Hg or taking antihypertensive agents); 
hypercholesterolemia (total cholesterol >5.0 mmol/L 
[193 mg/dL] or taking a lipid-lowering agent); or a his-
tory of gestational diabetes mellitus.1,9
High-risk patients were labeled as such in the elec-
tronic medical record. When visiting their family prac-
tice for a regular care consultation, high-risk patients 
were invited for screening using fasting plasma glucose 
testing. Screening was accepted in 90% of cases.12 
Diagnosis of type 2 diabetes was based on interna-
tional criteria, requiring 2 fasting plasma glucose mea-
surements on 2 separate days, both with a value ≥7.0 
mmol/L (≥126 mg/dL).13
Type 2 Diabetes by Clinical Diagnosis
Patients with clinically diagnosed type 2 diabetes 
had signs or symptoms of diabetes during a practice 
consultation. If they had classic symptoms of hyper-
glycemia (polyuria and polydipsia), a single, random, 
plasma glucose measurement of ≥11.1 mmol/L (≥200 
mg/dL) was sufﬁ cient for diagnosis. When they had 
milder symptoms (eg, fatigue, frequent infections, 
blurred vision), 2 fasting plasma glucose samples, on 
separate days and both ≥7.0 mmol/L (≥126 mg/dL), 
were required.13
Diabetes Treatment
Patients in both study groups received the same stan-
dard of diabetes care and were treated during routine 
care consultations by their own family physician and 
practice nurses. Diabetes care was in line with the fol-
lowing Dutch family practice guidelines for type 2 
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diabetes: recorded on intake and then yearly are family 
history, smoking status, and comorbidities; a physical 
examination; an ophthalmologic examination (fundus-
copy or fundus photography); laboratory testing for 
fasting blood glucose, hemoglobin A1c, lipids, plasma 
creatinine, and albuminuria; and education and life-
style advice. Three times a year patients have weight 
and blood pressure measured, fasting blood glucose 
and hemoglobin A1c tested if on insulin; and education 
and lifestyle advice. Glycemic control is undertaken 
to reduce hemoglobin A1c to less than 53 mmol/mol 
(<7.0%), using a stepwise approach with metformin 
as a ﬁ rst-choice agent when diet is insufﬁ cient; a sul-
phonylurea derivative or insulin is added, if necessary. 
For cardiovascular risk, the target systolic blood pres-
sure is less than 140 mm Hg. A statin is recommended 
unless untreated low-density lipoprotein cholesterol 
is less than 160 mg/dL (2.5 mmol/L) or the absolute 
10-year mortality risk is less than 5%. An angiotensin-
converting enzyme inhibitor is recommended for 
microalbuminuria even with normal blood pressure, 
and a platelet aggregation inhibitor is indicated for sec-
ondary prevention only.9
Defi nition of Outcomes
All data were collected from the NMP electronic data-
base. We used all clinical information available up to 
the end of 2009. The primary group outcome during 
follow-up was the composite of death from cardiovas-
cular disease (CVD), nonfatal myocardial infarction, 
and nonfatal stroke. Secondary outcomes included 
microvascular complications (diabetic retinopathy, 
neuropathy, and nephropathy), any ﬁ rst CVD event 
(nonfatal myocardial infarction, nonfatal stroke, heart 
failure, ischemic heart disease, transient cerebral isch-
emia, or peripheral arterial disease), all-cause death, 
and non-CVD death. Retinopathy was diagnosed with 
funduscopy or fundus photography by an ophthalmol-
ogist who reported the result to the family physician. 
Neuropathy was diagnosed by the family physician by 
physical examination in cases showing loss of monoﬁ la-
ment sensation in the toes. Nephropathy was deﬁ ned 
as a glomerular ﬁ ltration rate <60 mL/min/1.73 m2, 
estimated by the Modiﬁ cation of Diet in Renal Disease 
Study equation.14
Statistical Analysis
We analyzed participant characteristics at baseline and 
at the last follow-up visit using the Pearson χ2 or Fisher 
exact test for categorical data and the Student t test for 
means where appropriate. The main process and out-
come variables of care during follow-up were similarly 
analyzed.
To compare the primary and secondary outcomes 
between the 2 study groups, we calculated the inci-
dences of the events and applied the Pearson χ2 or 
Fisher exact test for statistical analysis.
In Cox regression models, hazard ratios for the out-
comes with their 95% conﬁ dence intervals and P values 
were calculated. Time to event was deﬁ ned as the time 
between date of diagnosis and date of cardiovascular 
event or death. For microvascular outcomes, the date 
of event was the date of diagnosis during follow-up. 
Patients were followed until death, loss to follow-up, or 
end of study (December 31, 2009). Hazard ratios were 
unadjusted and adjusted for 6 baseline variables: age, 
sex, CVD, fasting plasma glucose, systolic blood pres-
sure, and plasma creatinine.
We conducted all analyses in SPSS 16.0 for Win-
dows (SPSS Inc). All analyses were 2-sided, and we 
considered a P value <.05 to be signiﬁ cant.
RESULTS
Opportunistic targeted screening detected type 2 
diabetes in 359 patients. A clinical diagnosis of type 2 
diabetes based on signs or symptoms was found in 206 
patients (Table 1). Patients with clinically diagnosed 
type 2 diabetes were more likely to be men and were 
generally younger than patients with diabetes detected 
by screening.
At baseline, the prevalence of macrovascular disease 
was signiﬁ cantly higher in the opportunistic targeted 
screening group, which could be primarily explained 
by ischemic heart disease. Prevalence of diabetic reti-
nopathy and neuropathy was similar, but nephropa-
thy was more commonly found with opportunistic 
targeted screening. Mean systolic blood pressure and 
plasma creatinine were also signiﬁ cantly higher in the 
screening group. As expected, fasting blood glucose 
and hemoglobin A1c levels were signiﬁ cantly elevated 
in patients with clinically diagnosed diabetes. Other 
characteristics were similar at baseline.
Follow-up
Mean systolic blood pressure and plasma creatinine 
no longer differed between the opportunistic targeted 
screening and clinical diagnosis groups after a mean 
follow-up of 7.7 years (SD = 2.4 years) and 7.1 years 
(SD = 2.7 years) , respectively (Table 1). Glucose and 
cholesterol values had improved and smoking had 
decreased in both groups.
Process and Outcome Variables of Care
Processes of care were comparable between both study 
groups after follow-up (Table 2). With regard to out-
come variables, we found signiﬁ cantly better glycemic 
control among patients from the opportunistic targeted 
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screening group and less frequent insulin treatment, 
but a higher use of antihypertensive medications. 
Other outcomes of care did not differ signiﬁ cantly 
from those of the clinical diagnosis group.
Primary Outcomes
The composite primary event rates during follow-up 
did not differ signiﬁ cantly between the opportunistic 
targeted screening and clinical diagnosis groups (9.5% 
vs 10.2%, P = .78; adjusted hazard ratio [HR] = 0.67, 
95% CI, 0.36-1.25; P = .21; Table 3). The hazard 
curves, however, show a more steeply increasing risk 
for a major macrovascular event in patients with clini-
cally diagnosed diabetes (Figure 1).
Lower incidences and risk for nonfatal myocardial 
infarction and for nonfatal stroke were observed in the 
opportunistic targeted screening group, whereas risk 
for CVD death was higher. Because of the small num-
bers and a large conﬁ dence interval, the differences for 
CVD death were not statistically signiﬁ cant.
Secondary Outcomes
Microvascular event rates were also not signiﬁ -
cantly different between the study groups (Table 3), 
although incidence and risk for diabetic retinopathy 
were lower after opportunistic targeted screening 
(1.5% vs 3.9%; P = .08; adjusted HR = 0.75, 95% CI, 
0.19-3.08; P = .69).
Risk for any ﬁ rst CVD event did not differ signiﬁ -
cantly between the groups (Table 3). Lower incidences 
and risk were observed in the opportunistic targeted 
screening group for ischemic heart disease, whereas 
they were higher for heart failure, transient cerebral 
ischemia, and peripheral arterial disease, but these dif-
ferences were not statistically signiﬁ cant or the 95% 
conﬁ dence intervals were large (data not shown).
All-cause death rates did not differ signiﬁ cantly (8.6 
vs 10.7%; P = .42; adjusted HR = 0.60, 95% CI, 0.31-
1.13; P = .12), in contrast to non-CVD death (4.2% vs 
8.7%; P = .03; adjusted HR =  0.33, 95% CI, 0.15-0.71; 
P = .01; Table 3). We observed more deaths caused 
Table 1. Characteristics of Patients with Newly Diagnosed Type 2 Diabetes for Opportunistic Targeted 
Screening (n = 359) and Clinical Diagnosis (n = 206) Groups at Baseline and After Follow-up
Characteristic
Baseline Follow-up
Opportunistic 
Targeted 
Screening
Clinical 
Diagnosis
P 
Value
Opportunistic 
Targeted 
Screening
Clinical 
Diagnosis
P 
Value
Age, mean (SD), y 61.8 (7.8) 59.0 (8.1) <.001      
Sex (male), No. (%) 175 (48.7) 118 (57.3) .05      
Follow-up, mean (SD), y       7.7 (2.4) 7.1 (2.7) .01
History of macrovascular disease,a No. (%) 88 (24.5) 24 (11.7) <.001      
Ischemic heart disease, No. (%) 44 (12.3) 8 (3.9) .001      
Myocardial infarction, No. (%) 26 (7.2) 11 (5.3) .38      
Stroke, No. (%) 12 (3.3) 3 (1.5) .18      
Other, No. (%) 24 (6.7) 11 (5.3) .52      
History of microvascular disease,a No. (%) 63 (17.5) 24 (11.7) .06      
Retinopathy, No. (%) 1 (0.3) 3 (1.7) .12      
Neuropathy, No. (%) 6 (1.7) 8 (3.9) .10      
Nephropathy, No. (%) 57 (16.9) 13 (7.1) .002      
Blood glucose control            
FPG, mean (SD), mmol/L 8.8 (2.9) 12.9 (5.0) <.001 7.9 (1.7) 8.2 (2.2) .06
HbA1c, mean (SD),b mmol/mol 55 (17) 74 (28) <.001 51 (10) 54 (12) .001
HbA1c, mean (SD),b % 7.2 (1.6) 8.9 (2.5) <.001 6.8 (0.9) 7.1 (1.1) .001
CVD risk factors            
Current smoking, No. (%) 66 (19.3) 41 (21.9) .47 45 (13.5) 29 (15.8) .48
Systolic blood pressure, mean (SD), mm Hg 153 (20) 147 (21) .004 145 (18) 144 (17) .59
Diastolic blood pressure, mean (SD), mm Hg 86 (10) 85 (11) .33 80 (10) 81 (9) .16
BMI, mean (SD), kg/m2 30.5 (4.7) 29.7 (5.0) .07 29.9 (4.7) 29.6 (4.6) .51
Total cholesterol, mean (SD), mmol/L 6.0 (1.2) 6.0 (1.4) .38 4.7 (1.1) 4.7 (1.1) .58
LDL cholesterol, mean (SD), mmol/L 3.7 (1.1) 3.8 (1.2) .72 2.6 (1.0) 2.7 (0.9) .86
Plasma creatinine, mean (SD), mmol/L 88.7 (18.1) 84.1 (17.3) .004 89.4 (24.5) 87.4 (19.9) .32
Abbreviations: BMI = body mass index; CVD = cardiovascular disease; FPG = fasting plasma glucose; HbA1c = hemoglobin A1c; LDL = low-density lipoprotein.
a Some patients had multiple events.
b Missing at baseline = 201 in opportunistic targeted screening group; 126 in clinical diagnosis group.
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by infections or pulmonary disease (2.2% vs 1.5%) in 
the opportunistic targeted screening group but fewer 
deaths that were due to cancer (1.9% vs 7.3%). No 
speciﬁ c type of cancer could explain the higher preva-
lence in the clinical diagnosis group (data not shown).
DISCUSSION
This study is the ﬁ rst to compare patients from the 
same population with type 2 diabetes detected by 
either opportunistic targeted screening or by clinical 
signs or symptoms and observed for long-term vascular 
outcomes.
For patients with type 2 dia-
betes detected by opportunistic 
targeted screening who had 
higher CVD morbidity at base-
line, in particular ischemic heart 
disease and hypertension-related 
nephropathy, after up to 10 years 
follow-up, major macrovascular 
event rates did not signiﬁ cantly 
differ between the 2 groups. 
Secondary vascular event rates 
were also not signiﬁ cantly differ-
ent between groups, although the 
opportunistic targeted screening 
group did show a lower risk for 
diabetic retinopathy than the 
clinical diagnosis group.
Differences at diagnosis 
between patients with type 2 dia-
betes detected by screening and 
clinically were described earlier 
in the Hoorn Screening Study,15 a 
targeted diabetes screening study 
Table 2. Main Process and Outcome Variables of Care, at Last 
Follow-up for Opportunistic Targeted Screening (n = 359) and Clinical 
Diagnosis (n = 206) Groups
Variable
Opportunistic 
Targeted Screening
No. (%)
Clinical 
Diagnosis
No. (%)
P 
Value
Process of care      
HbA1c recorded 345 (96.1) 196 (95.1) .59
Systolic blood pressure recorded 349 (97.2) 197 (95.6) .32
LDL cholesterol recorded 332 (92.5) 182 (88.3) .10
Eye examination recorded 344 (95.8) 189 (91.7) .04
Foot examination recorded 348 (96.9) 192 (93.2) .04
Outcome of care      
HbA1c <53 mmol/mol (7.0%) 220 (63.8) 99 (50.5) .003
Systolic blood pressure <140 mm Hg 126 (36.1) 69 (35.0) .80
LDL cholesterol <2.5 mmol/L 159 (47.9) 81 (44.5) .46
Glucose-lowering treatment      
Diet only 96 (26.7) 34 (16.5) .01
Oral agent(s) 231 (64.3) 147 (71.4) .09
Insulin 19 (5.3) 26 (12.6) .002
Antihypertensive agent(s) 228 (71.2) 90 (52.3) <.001
Lipid-lowering agent(s) 216 (67.7) 109 (63.7) .38
HbA1c = hemoglobin A1c; LDL = low-density lipoprotein.
Table 3. Events After Diagnosis of Type 2 Diabetes for Opportunistic Targeted Screening (n = 359) and 
Clinical Diagnosis (n = 206) Groups  
Events
Incidence, No. (%)
Unadjusted HR
(95% CI)a
P 
Value
Adjusted HR
(95% CI)a
P 
Value
Opportunistic 
Targeted Screening
Clinical 
Diagnosis
P 
Value
Primary outcomes              
Major macrovascular 
eventb
34 (9.5) 21 (10.2) .78 0.84 (0.49-1.44) .52 0.67 (0.36-1.25) .21
CVD death 16 (4.5) 4 (1.9) .16 2.10 (0.70-6.28) .19 1.88 (0.41-8.57) .42
Nonfatal MI 11 (3.1) 11 (5.3) .18 0.54 (0.23-1.25) .15 0.43 (0.18-1.02) .06
Nonfatal stroke 10 (2.8) 9 (4.4) .32 0.57 (0.23-1.40) .22 0.68 (0.23-2.02) .49
Secondary outcomes              
Microvascular eventb 54 (17.1) 24 (15.2) .59 1.04 (0.64-1.68) .88 0.94 (0.55-1.60) .81
Retinopathy 5 (1.5) 7 (3.9) .08 0.32 (0.10-1.01) .05 0.75 (0.19-3.08) .69
Neuropathy 40 (11.5) 16 (8.3) .25 1.33 (0.74-2.37) .34 1.23 (0.63-2.39) .54
Nephropathy 18 (5.5) 10 (5.9) .87 0.86 (0.39-1.85) .69 0.93 (0.38-2.24) .87
Any fi rst CVDc 68 (18.9) 28 (13.6) .10 1.33 (0.86-2.07) .21 1.03 (0.63-1.67) .92
All-cause death 31 (8.6) 22 (10.7) .42 0.73 (0.42-1.26) .26 0.60 (0.31-1.13) .12
Non-CVD death 15 (4.2) 18 (8.7) .03 0.43 (0.22-0.85) .02 0.33 (0.15-0.71) .01
CVD = cardiovascular disease; HR = hazard ratio; MI = myocardial infarction.
a Hazard ratios with matching P values compare hazards in type 2 diabetes detected by opportunistic targeted screening with those in clinically diagnosed type 2 dia-
betes, unadjusted and adjusted for age, sex, and the following baseline characteristics: CVD, systolic blood pressure, fasting plasma glucose, and plasma creatinine.
b Some patients had multiple events.
c Nonfatal MI, nonfatal stroke, heart failure, ischemic heart disease, transient cerebral ischemia, or peripheral arterial disease.
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in the Netherlands. Our data conﬁ rmed the ﬁ ndings of 
the Hoorn Screening Study and showed that glucose 
levels were higher among patients with signs or symp-
toms at diagnosis, whereas retinopathy and neuropathy 
were equally prevalent in the 2 groups. Addition-
ally, these authors already noted strikingly prevalent 
macrovascular complications in patients with diabetes 
detected by screening.16
The major strength of our study was its particu-
lar setting. Although all NMP practices are afﬁ liated 
academically with the Radboud University Nijmegen 
Medical Centre, they are normal community prac-
tices with a population representative of the general 
Dutch population and a diabetes prevalence equal to 
that anywhere in the Netherlands.10,17 That the Dutch 
system of primary health care provides for universal 
access and continuity of patient registration enabled us 
to collect and present follow-up data from daily prac-
tice. The effectiveness of screening for type 2 diabetes 
should preferably be investigated in a randomized 
controlled trial.18 In the current absence of such trials 
and with limited evidence found in recent case-control, 
cross-sectional, and modeling studies,6 we believe that 
an observational study can provide important new 
data. Because we could show that patients in both 
study groups received the same level of diabetes care,9 
we were able to investigate outcomes related to time of 
diagnosis and early treatment.
Overall, we found lower vascular event rates than 
expected in both the opportunistic targeted screening 
group and the clinical diagnosis group. This ﬁ nding 
might reﬂ ect the impact of the guideline-concordant 
diabetes care in the practices, which includes cardio-
vascular risk management. Diabetes treatment had 
been successful in reducing blood pressure, smoking, 
and blood glucose and lipid levels in both groups.
We showed that the hazard curve of the primary 
outcome was higher for clinically diagnosed diabetes 
than for opportunistic targeted screening, which might 
be explained by lead-time bias: the longer interval 
between diagnosis and development of complications 
in patients detected by opportunistic targeted screen-
ing might be due to earlier detection in the natural 
history of the disease, instead of earlier treatment.19 
The lower glucose levels at diagnosis and lower risk 
for retinopathy for patients with diabetes detected by 
screening suggests that screening detects diabetes at an 
earlier stage of disease.2 Patients with diabetes detected 
by screening also tend to show milder disease and 
slower progression, with better clinical outcomes after 
follow-up (length-time bias).19 Although we screened 
patients in a high-risk population who had a higher 
initial prevalence of ischemic 
heart disease, nephropathy, and 
hypertension than patients in the 
clinical diagnosis group, vascular 
outcomes were similar between 
the groups upon follow-up. Even 
adjusted hazard ratios were not 
signiﬁ cantly different between 
groups. The opportunistic tar-
geted screening group may have 
developed diabetes complica-
tions caused by longer exposure 
to hyperglycemia as a result of a 
slower progression.
A ﬁ nal possibility is that 
patients who volunteer for 
screening programs are more 
health conscious and therefore 
more likely to have a better 
disease outcome even without 
screening (selection bias).19 The 
initiation of screening during 
routine care, the targeting of 
patients with diabetes risk fac-
tors, and the high response rate 
of 90%,8 all suggest that selec-
tion bias did not play a major 
role in our study. As previously 
Figure 1. Cumulative hazard of primary outcome following diagnosis 
of type 2 diabetes by opportunistic targeted screening, compared 
with clinical diagnosis.  
CVD = cardiovascular disease; HR = hazard ratio. 
Notes: Cumulative hazard of death from CVD, nonfatal myocardial infarction, or nonfatal stroke, adjusted for 
age, sex, and the following baseline characteristics: CVD, systolic blood pressure, fasting plasma glucose, and 
plasma creatinine.
Cu
m
u
la
ti
ve
 H
az
ar
d
 0 2 4 6 8 10 12
 Time Since Diagnosis, Years
HR = 0.67 (95% CI, 0.36-1.25); P = .21
0.20
0.15
0.10
0.05
0.00
Screening Clinically
ANNALS OF FAMILY MEDICINE ✦ WWW.ANNFAMMED.ORG ✦ VOL. 11, NO. 1 ✦ JANUARY/FEBRUARY 2013
26
VASCUL AR OUTCOMES IN T YPE 2 DIABETES
stated, however, patients with clinically diagnosed 
diabetes were more often men and were generally 
younger than patients with diabetes detected by 
opportunistic targeted screening. This difference may 
have been because only patients visiting the family 
practice were invited for screening, and younger men 
might be more likely to postpone a primary care con-
sultation. We adjusted data analyses for age and sex to 
account for this possible bias.
A selection bias that is due to a selective allocation 
to a group or treatment by the patient’s family physi-
cian is also unlikely, because patients were not random-
ized into a group, and although detection method was 
not blinded, it was recorded in the database for analy-
sis purposes only. Patients from both study groups 
received the same guided treatment during normal 
care from their own family physician, independent of 
the detection method.
A possible limitation may have been the diagnosis 
of type 2 diabetes by the fasting plasma glucose test 
rather than the oral glucose tolerance test. The oral 
glucose tolerance test consists of an fasting plasma 
glucose test and 2-hour plasma glucose value and is 
considered to be the reference standard test in the 
diagnosis of diabetes. The fasting plasma glucose test 
is more user-friendly, however, faster to perform, more 
convenient and acceptable to patients, and less expen-
sive. The recent American Diabetes Association rec-
ommendation to use hemoglobin A1c for screening was 
still under debate at the time of our study.1,20 Although 
later rectiﬁ ed, there was a large amount of data missing 
for hemoglobin A1c at baseline, because hemoglobin A1c 
was not yet registered in the database at the beginning 
of the study in 1998. The missing hemoglobin A1c val-
ues were comparable between groups, reﬂ ecting similar 
care, and the outcome was in line with the mean fast-
ing plasma glucose values at baseline.
With the exception of smoking, we were not able 
to investigate potential differences in lifestyle between 
groups, such as exercise or diet, because these data 
were not collected in the NMP database. Lifestyle 
advice is, however, an important part of the guided 
care in the practices.9
We have shown that within the ﬁ rst decade after 
diagnosis, in contrast to our expectations, opportu-
nistic targeted screening for type 2 diabetes resulted 
in similarly low macrovascular event rates compared 
with diabetes diagnosed on the basis of signs and 
symptoms. This central ﬁ nding of our study might be 
taken as an argument against screening. Even so, our 
ﬁ nding that higher CVD morbidity at baseline did not 
signiﬁ cantly increase vascular event rates after screen-
ing argues in favor of opportunistic targeted screening. 
We also showed that opportunistic targeted screening 
identiﬁ ed patients at an earlier stage of diabetes and 
that these patients had a lower risk for retinopathy dur-
ing follow-up. Furthermore, we found a trend toward a 
higher risk for a major macrovascular event in clinically 
diagnosed type 2 diabetes, and signiﬁ cant differences 
may yet become apparent over time.21
We have no explanation for the higher risk for 
non-CVD death (mainly caused by various types of 
cancer) in the group with clinically diagnosed diabetes. 
Although type 2 diabetes has been associated with 
an increased cancer risk, hyperglycemia could not be 
causally linked to this risk.22
Even though the overall statistical power of the 
study may not have been sufﬁ cient to detect small 
differences between groups, our observational study 
based on daily care did show some interesting results 
and trends. Further research is needed to investigate 
our ﬁ ndings in a larger setting and with a longer 
follow-up.
To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/content/11/1/20.
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